Also known as: autoimmune pancreatic diseases, Autoimmune pancreatic diseases
Researchers unveil pancreatic-targeted lipid nanoparticles using capsule filtration mechanisms, while a contract research organization expands lipid-based vector development services for organ-selective mRNA delivery.
Researchers developed pancreatic-targeted lipid nanoparticles (AH-LNP) that enable precise mRNA delivery to the pancreas through capsule-filter-mediated accumulation. The platform demonstrated efficacy in genome editing and cancer immunotherapy across multiple animal models including non-human primates.
